Ernexa Therapeutics Inc. reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge, MA
SEC filing record 1 source field available
Fiscal year end
31 December
Ernexa Therapeutics Inc. has filed 1,521 SEC EDGAR filings since 14 Feb 1994

SEC filing history

Showing 376-400 of 1,000 matching filings.

Per page
25
Current page
16
S-1 File 333-255694

S-1

Filing date
30 Apr 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K/A File 001-11460

8-K/A

Filing date
30 Apr 2021
Reporting date
25 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-11460

8-K

Filing date
30 Apr 2021
Reporting date
26 Apr 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-42217

SC 13G

Filing date
30 Apr 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-11460

8-K

Filing date
23 Apr 2021
Reporting date
21 Apr 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4

Filing date
20 Apr 2021
Reporting date
16 Apr 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3

Filing date
20 Apr 2021
Reporting date
16 Apr 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3

Filing date
19 Apr 2021
Reporting date
25 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3

Filing date
19 Apr 2021
Reporting date
25 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3

Filing date
16 Apr 2021
Reporting date
25 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-11460

8-K

Filing date
16 Apr 2021
Reporting date
12 Apr 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-11460

8-K

Filing date
15 Apr 2021
Reporting date
09 Apr 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-11460

8-K

Filing date
07 Apr 2021
Reporting date
01 Apr 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3

Filing date
05 Apr 2021
Reporting date
25 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3

Filing date
05 Apr 2021
Reporting date
25 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3

Filing date
05 Apr 2021
Reporting date
25 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3

Filing date
05 Apr 2021
Reporting date
25 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-11460

8-K

Filing date
31 Mar 2021
Reporting date
25 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
26 Mar 2021
Reporting date
24 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4

Filing date
26 Mar 2021
Reporting date
24 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-11460

8-K filing

Filing date
23 Mar 2021
Reporting date
23 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
22 Mar 2021
Reporting date
19 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
22 Mar 2021
Reporting date
19 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
SEC STAFF LETTER

SEC STAFF LETTER filing

Filing date
17 Mar 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D/A File 005-42217

AMENDMENT NO. 3

Filing date
17 Mar 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .